Syndax Valuation Multiples

Syndax Overview

About Syndax

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Founded

2005

HQ

Employees

270

Website

syndax.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $214M

EBITDA: ($243M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Syndax Financials

Syndax reported last 12-month revenue of $214M and negative EBITDA of ($243M).

In the same LTM period, Syndax generated $205M in gross profit, ($243M) in EBITDA losses, and had net loss of ($254M).

Syndax P&L

In the most recent fiscal year, Syndax reported revenue of $172M and EBITDA of ($252M).

Syndax expects next 12-month revenue of XXX and NTM EBITDA of XXX

Syndax Stock Performance

Syndax has current market cap of $2B, and enterprise value of $2B.

Syndax's stock price is $21.62.

Syndax Valuation Multiples

Syndax trades at 8.6x EV/Revenue multiple, and (7.6x) EV/EBITDA.

Syndax Financial Valuation Multiples

As of March 21, 2026, Syndax has market cap of $2B and EV of $2B.

Equity research analysts estimate Syndax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Syndax has a P/E ratio of (7.5x).

Syndax Margins & Growth Rates

Syndax's revenue in the last 12 month grew by 93%.

Syndax's revenue per employee in the last FY averaged $0.8M.

Syndax's rule of 40 is (21%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Syndax's rule of X is 118% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Syndax Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Syndax M&A Activity

Syndax acquired XXX companies to date.

Last acquisition by Syndax was on XXXXXXXX, XXXXX. Syndax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Syndax Investment Activity

Syndax invested in XXX companies to date.

Syndax made its latest investment on XXXXXXXX, XXXXX. Syndax invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).